Akebia Therapeutics, Inc.
AKBA
Rank in Stocks
#18001
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge,... Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
Share Price
$0.5328
Last synced: 2026-11-09
Market Cap
$147.64M
Change (1 day)
32.77%
Change (1 year)
-70.56%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Akebia Therapeutics, Inc. (AKBA)
Category
Healthcare
Operating Margin for Akebia Therapeutics, Inc. (AKBA)
Operating Margin as of November 2026 TTM: -6.91%
According to Akebia Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -6.91%. At the end of 2025 the company had an operating margin of 9.95%.
Operating Margin history for Akebia Therapeutics, Inc. from 2012 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -6.91% | -169.45% |
| 2025 | 9.95% | -131.58% |
| 2024 | -31.51% | 32.56% |
| 2023 | -23.77% | -13.94% |
| 2022 | -27.62% | -77.90% |
| 2021 | -124.97% | -2.54% |
| 2020 | -128.23% | 50.05% |
| 2019 | -85.46% | -0.34% |
| 2018 | -85.75% | 90.98% |
| 2017 | -44.90% | -99.49% |
| 2016 | -8,889.90% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -105.58% |
US
|
|
| -149.01% | -78.44% |
US
|
|
| 25.57% | -103.70% |
AU
|
|
| 31.23% | -104.52% |
BE
|
|
| 29.35% | -104.25% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Akebia Therapeutics, Inc.'s operating margin
What is Akebia Therapeutics, Inc.'s operating margin?
Akebia Therapeutics, Inc.'s operating margin is -6.91%, as of Nov 2026.
What was Akebia Therapeutics, Inc.'s operating margin in 2025?
In 2025, Akebia Therapeutics, Inc.'s operating margin was 9.95%, compared with -31.51% in 2024.
How has Akebia Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Akebia Therapeutics, Inc.'s operating margin was highest in 2025 (9.95%) and lowest in 2020 (-128.23%).
How does Akebia Therapeutics, Inc.'s operating margin compare with similar companies?
Akebia Therapeutics, Inc.'s operating margin (-6.91%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.